StartsidaAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
7,49 $
Efter stängningsdags:(1,06 %)+0,079
7,57 $
Stängt: 27 jan., 17:30:11 GMT−5 · USD · NASDAQ · Ansvarsfriskrivning
Föregående stängning
7,85 $
Dygnsintervall
7,40 $ - 8,01 $
Årsintervall
7,39 $ - 19,09 $
Börsvärde
721,75 mn USD
Genomsnittlig volym
1,47 mn
P/E-tal
-
Direktavkastning
-
Primär börs
NASDAQ
Ekonominyheter
24/7 Wall St.
för 1 timme sedan
5 of the Most Undervalued S&P 500 Stocks Also Pay High-Yield Dividends
1,46 %
Ekonomi
Resultaträkning
Intäkter
Nettoinkomst
| (USD) | sep. 2024info | Förändring Y/Y |
|---|---|---|
Intäkter | 50,02 mn | 613,22 % |
Rörliga kostnader | 44,20 mn | 5,21 % |
Nettoinkomst | −2,62 mn | 92,76 % |
Nettovinstmarginal | −5,25 | 98,98 % |
Vinst per aktie | −0,03 | 92,68 % |
EBITDA | 708,00 tn | 102,05 % |
Giltig skattesats | −3,47 % | — |
Balansräkning
Totala tillgångar
Totala ansvarsskyldigheter
| (USD) | sep. 2024info | Förändring Y/Y |
|---|---|---|
Kontanta och kortsiktiga investeringar | 65,81 mn | −57,04 % |
Totala tillgångar | 158,25 mn | −22,08 % |
Totala ansvarsskyldigheter | 83,59 mn | −10,07 % |
Totala tillgångar | 74,66 mn | — |
Utestående aktier | 96,36 mn | — |
P/B | 10,06 | — |
Avkastning på tillgångar | −0,52 % | — |
Avkastning på kapital | −0,73 % | — |
Kassaflöde
Förändring i nettokassa
| (USD) | sep. 2024info | Förändring Y/Y |
|---|---|---|
Nettoinkomst | −2,62 mn | 92,76 % |
Kontanter från verksamhet | −6,89 mn | 81,98 % |
Kontanter från investering | 4,93 mn | −49,80 % |
Kontanter från finansiering | 1,18 mn | −96,14 % |
Förändring i nettokassa | −265,00 tn | −114,51 % |
Fritt kassaflöde | −9,99 mn | 64,96 % |
Om
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Grundades
1990
Hemsida
Anställda
154
